POZ - CROI 2012 - Conference on Retroviruses and Opportunistic Infections - HIV - AIDS - Hepatitis

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
What you need to know
> Blogs > POZ TV > Treatment News > POZ Exclusives > Opinion

States of HIV

Disparities in HIV treatment initiation, viral load suppression vary across U.S.

Under Pressure

Hypertension greater heart attack risk in people with HIV.

Puffers Beware

HIV speeds lung function decline in study of mostly cigarette smokers.

Block that CCR5

Sangamo gene therapy continues to show well in Phase I studies.

Head to Head

All-in-one Quad tablet comparable to leading combo tablet Atripla.

Rear Results

A modified tenofovir gel safe and acceptable for rectal use in microbicide study.

Adherence Matters Most

Poor compliance hurts PrEP efficacy in high-risk women.

Breath Easy

Inhaled steroid for asthma & COPD found safe in combo with PIs.

Safe Shot

Shingles vaccine proves safe in people living with HIV and stable labs.

One Liver to Love

ARV liver toxicity in HIV/hep C patients on the decline.

Metformin Does Arteries Good

Diabetes medication halts plaque buildup in blood vessels.

Brain Drain

Minor cognitive problems can lead to daily functioning problems, study says.

Dolutegravir vs. Sustiva

ViiV's integrase comparable to a gold standard in treatment newbies.

Help for Hep

Incivek, Victrelis improve cure rates in HIV, hep C coinfection studies.

Antigen Answer

Drop in active hep B infection marker seen in tenofovir takers .

Tenofovir Part II

New tenofovir prodrug packs better, potentially safer punch vs. Viread.

Double Death Trouble

Black women twice as likely to die of AIDS in U.S. vs. white women.

Chemo Cure?

Anti-cancer drug Zolinza purges HIV from its hiding place.

Hepatitis Hiccup

12-week 7977/ribavirin course not enough for hep C geno 1 null responders.

Prevention for Partners

PrEP a success for hetero mixed-status couples.

On the Agenda

David Evans highlights a pre-CROI meeting to refine the role of activists in cure research strategies.

Coverage from
AIDSmeds & POZ

Clearing or Curing Acute HCV Does Not Protect Against Reinfection

Electrocauterization Has Fewer Side Effects, Better Efficacy, Than Topical Treatments for Anal Lesions

HCV Testing, Diagnosis Being Overlooked in People With HIV

Transmitted HIV Drug Resistance on the Rise in U.S.

Marker of Active Hep B Infection Declines in Those Coinfected with HIV, Treated with Tenofovir

Disparities in HIV Treatment Initiation, Viral Load Suppression Vary State-to-State

ARV Liver Toxicity in HIV/Hep C Coinfected Patients on the Decline

Treating HIV During Pregnancy Also Lowers Risk of Transmitting Hep C to Baby

Inhaled Beclomethasone Bests Fluticasone (Advair) When HIV PIs Being Used

GS 7340 Packs Greater HIV Punch, Potentially Better Safety, Versus Viread

Black Women Twice as Likely to Die of AIDS in U.S. Compared to White HIV-Positive Women

‘Quad’ Comparable to Norvir-Reyataz Regimen in Phase III Study

High Blood Pressure Increases Heart Attack Risk in HIV

HIV Speeds Lung Function Decline in Cohort of Smokers

Zostavax Shingles Vaccine Generally Safe, Increases Antibody Levels, in People With Stable HIV

Pathway to a Cure: Cancer Drug Helps Purge HIV From Resting Cells

Pathway to a Cure: Positive Results Continue for Sangamo’s CCR5 Gene Therapy

Diabetes Drug Metformin Prevents Worsening of Calcium Deposits in Arteries

Gilead Quad Performance Comparable to Atripla in First-Time Treatment Takers

CHARTER Study: Asymptomatic Cognitive Problems 'Harbinger' for Future Neurologic Decline

Poor Adherence Crippled PrEP Efficacy in Women’s Study

ViiV’s Dolutegravir Continues to Show Well After 96 Weeks, Versus Sustiva, for First-Time Treatment

12 Weeks of GS-7977 Plus Ribavirin Not Effective for Null Responders With Hep C Genotype 1

Modified Tenofovir Gel for Rectal Use Safe and Acceptable in Phase I Study

Partners PrEP: Up to 90% Fewer Infections in Mixed-Status Hetero Couples

Incivek, Victrelis Studies Hint at Superior Cure Rates in HIV/HCV Coinfection

> More Newsfeed
The Treatment Action Group (TAG) bestows its annual Research in Action Awards (RIAA) in New York City.
JOIN US Facebook Twitter YouTube
18th Conference on Retroviruses and Opportunistic Infections (CROI 2011)
Boston, MA
February 27 - March 2, 2011

17th Conference on Retroviruses and Opportunistic Infections (CROI 2010)
San Francisco, CA
February 16 - 19, 2010

16th Conference on Retroviruses and Opportunistic Infections (CROI 2009)
Montreal, Canada
February 8 - 11, 2009

more conference coverage
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2016 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.